Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 37

ROCKET AF: Primary Outcomes

The Forrest plot in the Figure shows the results of the comparison of rivaroxaban versus warfarin as non-inferiority and/or superiority, for the 3 predefined methods of analysis in ROCKET AF.[97] This shows in graphic form that that rivaroxaban is noninferior to warfarin by both per-protocol and ITT analysis, and superior to warfarin by safety on-treatment analysis, just missing statistical superiority (p=0.12) in the ITT analysis.  Thus it appears that rivaroxaban is at least non-inferior to warfarin, and in some respects meets the superiority level seen with the other agents we are discussing.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[97] Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

Unable to display view foot.php file not found.